Shares Are Gaining Today

Mainz Biomed N.V. MYNZ inked a pact with Liquid Biosciences, a bio-analytics company leveraging its proprietary AI analysis technology platform (EMERGE), to enhance the detection and diagnosis of colorectal cancer (CRC). Key attributes of EMERGE that make it superior to mainstream AI and machine…#emerge #crc #key #mainzbiomed #colofuture #fda #liquidbiosciences #guidobaechler
Source: Reuters: Health - Category: Consumer Health News Source Type: news